[{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Quintiles Inc | United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"UV-4B","moa":"Alpha-glucosidase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Emergent BioSolutions \/ Quintiles Inc | United Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Quintiles Inc | United Therapeutics"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"UV-4B","moa":"Alpha-glucosidase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)","moa":"Botulinum toxin","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ ASPR"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulism Antitoxin Heptavalent","moa":"BTX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Chimerix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Chimerix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Funding","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.69999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.69999999999999996,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Funding","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Humanigen"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ad4-mgag","moa":"HIV-1 Gag antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Ad4-mgag","moa":"HIV-1 Gag antigen","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"COVID-Higiv","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Zika Virus Immunoglobulin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Emergent BioSolutions","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Emergent BioSolutions \/ AstraZeneca"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"AVP-21D9","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Centers for Disease Control and Prevention | Department of Health and Human Services | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Raxibacumab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Centers for Disease Control and Prevention | Department of Health and Human Services | GSK","highestDevelopmentStatusID":"11","companyTruncated":"Emergent BioSolutions \/ Centers for Disease Control and Prevention | Department of Health and Human Services | GSK"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Emergent BioSolutions \/ Johnson & Johnson"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Providence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Providence Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Providence Therapeutics"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Vaxart","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Undisclosed","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"ACAM2000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Centers for Disease Control and Prevention","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"ACAM2000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"ACAM2000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Emergent BioSolutions \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ US Government"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Emergent BioSolutions \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Emergent BioSolutions \/ GSK"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institute of Allergy and Infectious Diseases | Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"AV7909","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases | Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institute of Allergy and Infectious Diseases | Department of Health and Human Services"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Biothrax","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Biothrax","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Cholera Vaccine, Live, Oral","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"11","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Hyperimmune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"COVID-Hig","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Walter Reed Army Institute of Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PXVX0047","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Walter Reed Army Institute of Research","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Walter Reed Army Institute of Research"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PXVX0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"PXVX0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"PXVX0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PXVX0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"CDMRP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Alhydrogel","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ CDMRP","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ CDMRP"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M Vaccine, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Novavax"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Emergent BioSolutions \/ Vaxart"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"RocketVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"RVX-13","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ RocketVax","highestDevelopmentStatusID":"4","companyTruncated":"Emergent BioSolutions \/ RocketVax"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Smallpox and Mpox Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"Typhoid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.38,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.38,"dosageForm":"Capsule","sponsorNew":"Emergent BioSolutions \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Bavarian Nordic"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"Typhoid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.38,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.38,"dosageForm":"Capsule","sponsorNew":"Emergent BioSolutions \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Bavarian Nordic"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"UFluA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"Vaccinia Immune Globulin, Human","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"VLA1601","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Emergent BioSolutions","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VSV-vectored Lassa Virus Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Yale University"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Tablet, Film Coated","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"}]
Find Clinical Drug Pipeline Developments & Deals by Emergent BioSolutions
Details :
The agreement aims to supply Tembexa (brincidofovir), an oral antiviral approved by the FDA in June 2021 for the treatment of human smallpox disease.
Details :
The agreement aims to supply ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live), a single-dose vaccine administered percutaneously, to the U.S. government.
Details :
The agreement aims to supply Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted), a vaccine indicated for post-exposure prophylaxis of anthrax disease.
Product Name : Cyfendus
Product Type : Vaccine
Upfront Cash : Undisclosed
September 02, 2025
Lead Product(s) :
Anthrax Vaccine Adsorbed, Adjuvanted
Details :
Vigiv (vaccinia immune globulin, human), indicated for the treatment of complications due to vaccinia vaccination, including Eczema vaccinatum.
Details :
BAT is a mixture of immune globulin fragments indicated for symptomatic botulism following exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.
Product Name : BAT
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 23, 2025
Lead Product(s) :
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)
Details :
Under the terms of the agreement, Emergent will be responsible for the distribution of Kloxxado (Naloxone HCl). It is being indicated for the treatment of known or suspected opioid overdose.
Details :
The funding aims for the drug product process and analytical testing validation and stability for Ebanga (ansuvimab). It is indicated for the treatment of infection caused by Zaire Ebola virus.
Details :
The agreement aims to supply BioThrax (Anthrax Vaccine Adsorbed), a vaccine indicated for the active immunization for the prevention of disease caused by Bacillus anthracis.
Details :
Tembexa (brincidofovir) is an antiviral medical countermeasure that is part of Emergent’s product portfolio and will be evaluated for the safety and efficacy in treating mpox virus.